NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

It is a valid concern, especially if:

1. SueVaxM is off-the-shelf. (Renders DCVax production hoops unnecessary)
2. Cheaper
3. Equally safe
4. ECA'S now becoming acceptable, a control may not be as indispensable.
5. How does this potential therapy, which looks dynamite thus far, influence any BP engagement, now and down the road?
6. Can SurVaxM render DCVAX as a platform less viable?

ILT